Physician profile
Angad Singh
NPI 1033793161
$1,266.22
in general payments reported to CMS, 2019-2025
17 companies · $396 in 2025
The $396 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $150 · 2024: $720 · 2025: $396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $947 · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $947.36 |
| Education | $168.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $225.27 | 2024-2025 | Uptravi, Opsumit |
| Genzyme Corporation | $203.60 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $184.25 | 2024-2025 | Dupixent |
| Sanofi-Aventis U.S. LLC | $124.11 | 2022 | |
| United Therapeutics Corporation | $121.85 | 2024-2025 | Tyvaso, Tyvaso |
| Merck Sharp & Dohme LLC | $85.18 | 2024-2025 | Zerbaxa, Winrevair, Dificid |
| Astrazeneca Pharmaceuticals LP | $79.42 | 2024-2025 | Fasenra, Tezspire |
| Mallinckrodt Hospital Products INC. | $38.95 | 2024 | Acthar |
| Ani Pharmaceuticals, INC. | $31.49 | 2024 | Purified Cortrophin Gel |
| E.R. Squibb & Sons, L.L.C. | $25.77 | 2022 | |
| Radius Health, INC. | $24.79 | 2024 | Tymlos |
| Edwards Lifesciences Corporation | $24.37 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Jazz Pharmaceuticals INC. | $21.29 | 2024 | |
| Abbvie INC. | $20.59 | 2024 | |
| Viatris Specialty LLC | $20.08 | 2025 | Yupelri |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.79 | 2025 | Jascayd |
| Mylan Specialty L.P. | $17.42 | 2024 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angad Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.